Mamta Kalra, PhD
Job Title: Director, Department of Chemistry, Manufacture and Control (CMC)
Current Employer: Immatics US Inc.
Postdoctoral training, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
Ph.D. Immunology, Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA
M.S. Medical Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA
B.S. Biology & Chemistry, M.C.M.D.A.V College for Women, Panjab University, Chandigarh, INDIA
After completing my doctoral research in TB vaccine development in India, I moved to United States and transitioned from the field of Infectious disease Immunology to Cancer Immunology. During my initial postdoctoral years, I studied the immunomodulatory role of estrogen in HCV-related liver cancer at Center for Health Sciences, Oklahoma State University. Subsequently, I got an opportunity to join Dr Stephan Gottschalk’s lab at the Center for Cell and Gene Therapy, Baylor College of Medicine. Here, the primary focus of my research was adoptive T-cell therapy for treatment of Epstein Barr Virus positive malignancies. However, my involvement gradually expanded to other clinical trials including Chimeric Antigen Receptor (CAR) T cells against solid tumors. This training equipped me with highly useful skills and experience in the field of cancer immunotherapy and helped me earn a Sr Scientist position at Immatics, a TCR-T cell therapy. Since my joining in April 2016, I have grown in my role and responsibilities at Immatics and presently serve as a Director in CMC department. In my current role, I have a privilege to lead a group of scientists and research associates and work closely with clinical and regulatory teams for developing autologous and allogeneic T-cell products.
Most useful skill sets acquired from/for your field:
Prioritization and planning
Working in cross-functional teams
What I love most about my job:
Pioneering therapies with a group of exceptional people who work together with great passion and responsibility to fulfill our mission of delivering the power of T cells to cancer patients.